Cargando…

Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab

The treatment of advanced non-small cell lung cancer (NSCLC) has been revolutionized by immune checkpoint inhibitors (ICIs). The identification of prognostic and predictive factors in ICIs-treated patients is presently challenging. Circulating tumor cells (CTCs) and cell-free DNA (cfDNA) were evalua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alama, Angela, Coco, Simona, Genova, Carlo, Rossi, Giovanni, Fontana, Vincenzo, Tagliamento, Marco, Dal Bello, Maria Giovanna, Rosa, Alessandra, Boccardo, Simona, Rijavec, Erika, Biello, Federica, Longo, Luca, Cavalieri, Zita, Bruzzo, Cristina, Grossi, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679117/ https://www.ncbi.nlm.nih.gov/pubmed/31295929 http://dx.doi.org/10.3390/jcm8071011

Ejemplares similares

Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System
por: Truini, Anna, et al.
Publicado: (2014)

Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
por: Genova, Carlo, et al.
Publicado: (2019)

Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
por: Ottonello, Selene, et al.
Publicado: (2020)

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy
por: Coco, Simona, et al.
Publicado: (2017)

The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients
por: Dal Bello, M. G., et al.
Publicado: (2019)

Serum levels of VCAM‐1 are associated with survival in patients treated with nivolumab for NSCLC
por: Carbone, Federico, et al.
Publicado: (2021)

Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer
por: Coco, Simona, et al.
Publicado: (2019)

Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab
por: Cusato, Jessica, et al.
Publicado: (2019)

Reply to the Letter to the Editor by C. Nicolazzo et al.: “Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy”
por: Alama, Angela, et al.
Publicado: (2017)

Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report
por: Vanni, Irene, et al.
Publicado: (2016)

A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients
por: Marconi, Silvia, et al.
Publicado: (2022)

The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab
por: Bauckneht, Matteo, et al.
Publicado: (2021)

Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform
por: Vanni, Irene, et al.
Publicado: (2015)

Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges
por: Rijavec, Erika, et al.
Publicado: (2019)

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
por: Rebuzzi, Sara Elena, et al.
Publicado: (2021)

Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples
por: Bonfiglio, Silvia, et al.
Publicado: (2016)

Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients
por: Dono, Mariella, et al.
Publicado: (2019)

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib
por: Rijavec, Erika, et al.
Publicado: (2022)

Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
por: Genova, Carlo, et al.
Publicado: (2023)

Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma
por: Truini, Anna, et al.
Publicado: (2017)

Inhibition of the Nicotinic Acetylcholine Receptors by Cobra Venom α-Neurotoxins: Is There a Perspective in Lung Cancer Treatment?
por: Alama, Angela, et al.
Publicado: (2011)

Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I–III Non-Small Cell Lung Cancer
por: Grossi, Francesco, et al.
Publicado: (2015)

Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy
por: Grossi, F, et al.
Publicado: (2017)

Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review
por: Indini, Alice, et al.
Publicado: (2021)

Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
por: Rossi, Giovanni, et al.
Publicado: (2020)

Clinical relevance and biology of circulating tumor cells
por: Bednarz-Knoll, Natalia, et al.
Publicado: (2011)

Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset
por: Agnoletto, Chiara, et al.
Publicado: (2019)

Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients
por: Puzone, Roberto, et al.
Publicado: (2013)

Molecular phenotypes of circulating tumor cells and efficacy of nivolumab treatment in patients with head and neck squamous cell carcinoma
por: Tada, Hiroe, et al.
Publicado: (2020)

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
por: Nicolazzo, Chiara, et al.
Publicado: (2016)

On the clinical relevance of circulating endothelial cells and platelets in prostate cancer
por: Bertolini, F, et al.
Publicado: (2013)

Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management
por: Cieślikowski, Wojciech A., et al.
Publicado: (2021)

Clinical relevance of circulating angiogenic cells in patients with ischemic stroke
por: Rodríguez-Esparragón, Francisco, et al.
Publicado: (2022)

Circulating tumour cells for early detection of clinically relevant cancer
por: Lawrence, Rachel, et al.
Publicado: (2023)

Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
por: Capone, Mariaelena, et al.
Publicado: (2020)

Reply: On the clinical relevance of circulating endothelial cells and platelets in prostate cancer
por: Wong, C K E, et al.
Publicado: (2013)

Clinical relevance of circulating cell-free microRNAs in ovarian cancer
por: Nakamura, Koji, et al.
Publicado: (2016)

Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer
por: Papadaki, Maria A., et al.
Publicado: (2020)

Relevance of Circulating Tumor Cells as Predictive Markers for Cancer Incidence and Relapse
por: Chelakkot, Chaithanya, et al.
Publicado: (2022)

Epithelial Cell Adhesion Molecule: An Anchor to Isolate Clinically Relevant Circulating Tumor Cells
por: Eslami-S, Zahra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_69dvmsisrr4sa3n6sh59j428rb